BIO KOREA 2021 (June 9 (Wed) – 21 (Mon), 2021)

BIO KOREA has been held every year since 2006 and serving as a business platform for international bio companies. Sponsored by the Ministry of Health and Welfare, BIO KOREA is a place of practical business correspondence as well as international information and technology exchange, invigorating the bio industry. In its 15th year of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, through exhibition, business forum(partnering), and conference.

BIO KOREA has been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology. We cordially invite you to attend BIO KOREA 2021 which will be held both online (June 9-21, 2021) and on-site (June 9-11, 2021).

www.biokorea.org

6th KAPAL On-Air Webinar (Apr 29, 2021, 9:00 – 10:30 PM EST)

2021 KAPAL–KHIDI Bio & Health Webinar Series #1

When: 04/29/2021, 9:00pm – 10:30pm (EST)
04/29/2021, 6:00pm – 7:30pm(PST)
04/30/2021, 10:00am – 11:30am(KST)

Speaker : Stanford Jhee (Corporate Vice President, Scientific Affairs, Parexel International)

Title: Accelerating Global drug development: Ethnobridging strategies for Asia.

Objectives

  1. Define and understand ethnic sensitivity issues in drug development
  2. Regulatory updates on Japan and China clinical trials and product registration
  3. Clinical pharmacology strategies for identifying ethnicity factors

6th KAPAL On-Air webinar materials will be posted later.

5th KAPAL On-Air Webinar (Dec 29, 2020, 8:00 – 9:30 PM EST)

2020년 카팔의 온에어웨비나 시리즈에서 주제가 되었던 내용을 정리하고 한해를 마무리하며 네트워킹하는 웨비나입니다.

About this Event

안녕하세요.

어느새 2020년을 마무리하고 2021년을 기다리는 시간이 돌아왔네요.  

연말연시 모든 가정과 일터에 읏음과 행복으로 가득하길 바랍니다. 2020년을 되돌아보면 예상치 않던 코비드19로 인해 우리 생활에 많은 변화와 어려움도 있었지만, 새로운 도전도 많았던 한해 같습니다.

다행히도 코비드19 백신에 초록불이 켜졌고, 치료제 개발에도 많은 좋은 뉴스들이 나오고 있으니, 앞으로는 더욱 밝은 내용의 뉴스들을 듣길 기대하며 2021년을 준비하는 마음입니다. 오랜 펜더믹 상황에 너무 마음과 몸이 지치셨겠지만, 조금 더 힘을 내어 우리 모두 건강하게 잘 이겨내길 진심으로 바랍니다.  

저희 카팔은 오는 12월 29일 (화요일 미국동부시간 오후 8시,서부 오후 5시, 한국 12/30일 오전 10시 )에  제 5 회 카팔 온에어 웨비나를 개최합니다.  

https://www.eventbrite.com/e/5th-kapal-on-air-webinar-tickets-132679623325

이번 웨비나에서는 2020년 한해동안 진행한 4회의 웨비나를 정리를 하여 발표준비하고 있습니다.  또한 소그룹 네트워킹 시간과 상품권 추천 (총 1000불상당)을 준비하였으니 바쁘시더라도 관심과 참석을 바랍니다.

카팔은 2020년 아래의 주제들로 웨비나를 4회 개최하였습니다. 

아래는 지난 KAPAL 온에 웨비나 링크입니다.

KAPAL 4th On-Air Webinar (매사추세츠)

KAPAL 3rd On-Air Webinar (캘리포니아)

KAPAL 2nd On-Air Webinar (메릴랜드)

KAPAL 1st On-Air Webinar (코비드 진단키트 EUA)

카팔의 더 많은 정보는 www.kapal.org 에서 보실 수 있습니다.

4th KAPAL On-Air webinar materials – Boston’s Biotech & Pharmaceutical Cluster (Presentation slides and recordings)

지난 12월 1일 “한국 바이오 기업들이 매사추세 주 (보스톤) 진출에 이로운 이점과 전략” 을 주제로 4th KAPAL On-Air webinar가 진행되었습니다.

보스톤시에서 제공하는 다양한 혜택과 정보들을 안내드리고, 보스톤 이미 정착해 성장하고 있는 한국기업들 (GENESCO, ORUM Therapeutics, and INGENIA Therapeutics) 초청하여 다양한 사례를 들어보는 시간을 가졌습니다. 더불어 매스바이오 (Mass Bio)에 Ben Bradford (Vice President)가 보스톤 생명과학기업 현황에 대해 발표 드렸습니다.

회원 여러분들의 많은 관심과 도움으로 각 Webinar에 260여명이 참석하셔서 많은 질의 응답이 진행되는 등 성황리에 완료 되었습니다.

4th KAPAL On-Air webinar materials (Presentation slides and recordings)은 아래 링크를 통하여 다운로드하시거나 재 시청하실 수 있습니다.

도움 주시고 참여해주신 모든 분들께 다시 한번 감사의 인사를 드립니다.

Jong Sung Koh, Ph.D.
CEO at GENOSCOS

Dr. Jong Sung Koh is the CEO at GENOSCO (www.genosco.com ), Inc. with Ph.D. degree from California Institute of Technology (Caltech). Prior to GENOSCO, he served as the vice president and member of the executive management team at LG Life Sciences from 2002 to 2007 in Korea and head of the Anti-cancer Research Center at Korea Research Institute of Chemistry and Technology (KRICT, 2007-2008). He has over 30 years of pharmaceutical industry experience, during which his works have led to identification of drug and numerous drug candidates, including Gemigliptin (Zemiglo), a successfully marketed drug in Korea for the treatment of diabetes (90 million dollar sales in Korea), historic record sales in Korean drug discovery history and Lazertinib, a lung cancer drug that was licensed to J&J’s Janssen valued up to 1.25 billion dollars. Lazertinib is in pivotal trial for the approval of FDA in non-small cell lung cancer. Dr. Koh founded Korean American Bio Industrial Council (KABIC: www.kabic.org ), a non-profit organization headquartered in Boston, Massachusetts, in 2011. KABIC becomes a main network hub for Korean and Korea-American healthcare professionals and enterprises. He served as the president for 7 years and is serving as a special advisor since 2018.

Sung Joo Lee, Ph.D.
CEO at Orum Therapeutics

Orum Therapeutics is a private biotech company located in Daejeon, Korea, and Cambridge, Massachusetts. We are developing a novel class of therapeutic antibodies to bring new medicines to patients with unmet medical needs. Orum (오름) means ‘ascent’ in Korean, and it represents to us the idea of climbing or moving upwards. In 2016, we were founded with the goal of discovering the antibodies against undruggable targets. We named our company Orum, because we believe that inhibiting undruggable targets with antibody drugs is akin to climbing K2, one of the most dangerous mountains in the world. K2 was insurmountable for nearly 100 years, until its first climbers used oxygen tanks in 1952. We believe Orum possesses the ‘oxygen tank,’ but requires further perseverance, determination and teamwork in order to complete our ascent.
Our vision is a world where no patient suffers from diseases caused by undruggable targets.

Sangyeul Han, Ph.D.
CEO/Co-founder, INGENIA Therapeutics Inc., USA

Sangyeul Han is currently the Co-Founder & CEO at INGENIA Therapeutics Inc., a biotech startup, established to develop innovative therapeutic antibodies. He received his B.S., M.S., and Ph.D. degrees in Molecular Biology from Seoul National University, South Korea, where his research focused on investigating the regulatory mechanism of secretory protein trafficking. In 2002, he started his postdoctoral research at the Massachusetts General Hospital/Harvard Medical School where he studied the pathological mechanisms of several tumor suppressor syndromes, including Tuberous Sclerosis Complex (TSC), Neurofibromatosis (NF), and chordomas as a research fellow/instructor. In 2010, he then joined the Biotherapeutics lab at Samsung Advanced Institute of Technology, South Korea, where he led a project for the development of therapeutic antibodies for multiple diseases. In 2016, he moved to Cell Signaling Technology, USA, where he led Antibody Technology group & Molecular Biology group. He is an author of 20+ publications in scientific journals and an inventor on multiple patents in the area of therapeutic antibody development. His expertise lies in R&D of therapeutic antibodies, vascular biology, & cancer biology.

Ben Bradford
Vice President of Membership and Economic Development, MassBio

Ben joined the MassBio team in 2017. As Vice President of Membership and Economic Development, he oversees the recruitment of new member companies and the Member Services team’s efforts to maximize the membership needs of existing members. He also works with member and non-member companies to support their decision making on relocation or expansions. Through relationships with foreign economic development agencies, Ben works to connect foreign companies to the US market. Prior to MassBio, Ben worked as Director of Business Development and Regional Strategy at the Massachusetts Life Sciences Center where he was responsible for recruiting new companies to do business in Massachusetts and developing relationships with municipalities across the Commonwealth with the goal of expanding the industry state-wide. Ben has a B.A. in Political Science from Union College(NY). He lives in North Reading with his wife and two kids.

4th KAPAL On-Air Webinar – Boston’s Biotech & Pharmaceutical Cluster – Benefits, Strategy, and Networking (Dec 1, 2020, 8:00 – 10:00 PM EST)

Massachusetts Biotech & Pharma Cluster 온라인 설명회는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

About this Event

안녕하세요. 이제 연말이 성큼 다가온 11월말입니다. 추운 겨울이지만 가족, 친지들과 따스한 연말을 맞이하시길 저희 한미 생명과학인 협회(KAPAL)는 진심으로 바랍니다.

“KAPAL 4th On-Air Webinar”가 돌아오는 12월 1일 미동부 시간으로 오후 8시에 개최됩니다 (미서부시간 오후 5시, 한국시간 12월 2일 오전 10:00 시).

제 4 회 카팔 웨비나는 “한국 바이오 기업들이 매사추세 주 (보스톤) 진출에 이로운 이점과 전략” 을 주제로, 보스톤지에서 제공하는 다양한 혜택과 정보들을 발표합니다. 뿐 아니라 보스톤 이미 정착해 성장하고 있는 한국기업들 (GENESCO, ORUM Therapeutics, and INGENIA Therapeutics) 초청하여 다양한 사례를 들어보는 시간을 준비하였습니다.

더불어 매스바이 (Mass Bio)에 Ben Bradford (Vice President)가 보스톤 생명과학기업 현황에 대해 발표를 할 계획이니 많은 참석 부탁드립니다.

웨비나 끝 순서로는 모든 발표자분들과 Q&A 시간을 통해 궁금하셨던 사항과 다양한 의견들을 자유롭게 나누는 시간이 준비 되어있습니다.

미리 이번 웨비나에 관련하여 Q&A 궁금하신 사항이나 질문들을 contact@kapal.org 로 보내주시면, 저희가 의견들을 수렴하여 더욱 알찬 웨비나를 만드는데 도움이 될 것입니다.

아래는 지난 KAPAL 온에 웨비나 링크입니다.

KAPAL 3rd On-Air Webinar (캘리포니아)

KAPAL 2nd On-Air Webinar (메릴랜드)

카팔의 더 많은 정보는 www.kapal.org 에서 보실 수 있습니다.